​

Revolution Medicines (RVMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RVMD Stock Forecast

Revolution Medicines (RVMD) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $165.75, with a high of $205.00 and a low of $73.00. This represents a 14.95% increase from the last price of $144.19.

- $50 $100 $150 $200 $250 High: $205 Avg: $165.75 Low: $73 Last Closed Price: $144.19

RVMD Stock Rating

Revolution Medicines stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 1 Strong Buy (4.55%), 20 Buy (90.91%), 1 Hold (4.55%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 1 20 1 Strong Sell Sell Hold Buy Strong Buy

RVMD Price Target Upside V Benchmarks

TypeNameUpside
StockRevolution Medicines14.95%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts61226
Avg Price Target$179.50$179.42$145.08
Last Closing Price$144.19$144.19$144.19
Upside/Downside24.49%24.43%0.62%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 264171--22
May, 26417---21
Apr, 26416---20
Mar, 26416---20
Feb, 26416---20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 09, 2026Michael YeeUBS$175.00$148.4517.88%21.37%
Jun 02, 2026Leonid TimashevRBC Capital$182.00$163.6811.19%26.22%
Jun 01, 2026H.C. Wainwright$195.00$162.5119.99%35.24%
Jun 01, 2026Oppenheimer$195.00$157.4823.83%35.24%
May 21, 2026Jeffrey WalchBernstein$151.00$153.73-1.78%4.72%
May 18, 2026Truist Financial$179.00$145.6622.89%24.14%
May 07, 2026Guggenheim$205.00$151.0735.70%42.17%
Apr 14, 2026Guggenheim$175.00$136.3028.39%21.37%
Apr 14, 2026Evercore ISI$200.00$136.3046.74%38.71%
Apr 14, 2026RBC Capital$162.00$136.3018.86%12.35%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 09, 2026UBSBuyBuyhold
Jun 02, 2026RBC CapitalOutperformOutperformhold
Jun 01, 2026H.C. WainwrightBuyBuyhold
Jun 01, 2026WedbushOutperformOutperformhold
Jun 01, 2026Cowen & Co.BuyBuyhold
Jun 01, 2026OppenheimerOutperformOutperformhold
May 21, 2026BernsteinMarket Performinitialise
May 07, 2026GuggenheimBuyBuyhold
Apr 14, 2026GuggenheimBuyBuyhold
Apr 14, 2026Evercore ISIOutperformOutperformhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.47$-3.08$-3.86$-3.58$-5.95---
Avg Forecast$-2.50$-3.29$-3.48$-3.47$-3.93$-4.05$-3.71$-1.65
High Forecast$-2.50$-3.29$-3.29$-3.36$-3.72$-2.37$1.56$-1.65
Low Forecast$-2.50$-3.29$-3.77$-3.96$-4.58$-4.64$-6.12$-1.65
Surprise %-1.20%-6.38%10.92%3.17%51.40%---

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$29.39M$35.38M$11.58M-----
Avg Forecast$28.78M$27.86M$12.65M$300.00K$5.87M$19.77M$178.13M$589.38M
High Forecast$28.78M$27.86M$17.96M$300.00K$5.87M$19.77M$178.13M$589.38M
Low Forecast$28.78M$27.86M$11.52M$300.00K$5.87M$19.77M$178.13M$589.38M
Surprise %2.11%26.98%-8.47%-----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-187.09M$-248.71M$-436.37M$-600.09M$-1.13B---
Avg Forecast$-168.05M$-186.58M$-436.37M$-414.33M$-469.55M$-396.42M$-608.95M$-186.78M
High Forecast$-134.44M$-149.26M$-349.09M$-380.55M$-420.48M$-267.64M$176.54M$-186.78M
Low Forecast$-201.66M$-223.89M$-523.64M$-448.11M$-518.62M$-525.20M$-692.17M$-186.78M
Surprise %11.33%33.30%-44.83%140.93%---

RVMD Forecast FAQ

Is Revolution Medicines stock a buy?

Revolution Medicines stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 20 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Revolution Medicines is a favorable investment for most analysts.

What is Revolution Medicines's price target?

Revolution Medicines's price target, set by 22 Wall Street analysts, averages $165.75 over the next 12 months. The price target range spans from $73 at the low end to $205 at the high end, suggesting a potential 14.95% change from the previous closing price of $144.19.

How does Revolution Medicines stock forecast compare to its benchmarks?

Revolution Medicines's stock forecast shows a 14.95% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Revolution Medicines over the past three months?

  • June 2026: 18.18% Strong Buy, 77.27% Buy, 4.55% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 19.05% Strong Buy, 80.95% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Revolution Medicines’s EPS forecast?

Revolution Medicines's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.05, marking a -31.93% decrease from the reported $-5.95 in 2025. Estimates for the following years are $-3.71 in 2027, and $-1.65 in 2028.

What is Revolution Medicines’s revenue forecast?

Revolution Medicines's average annual revenue forecast for its fiscal year ending in December 2026 is $19.77M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $178.13M, and $589.38M for 2028.

What is Revolution Medicines’s net income forecast?

Revolution Medicines's net income forecast for the fiscal year ending in December 2026 stands at $-396M, representing a -64.96% decrease from the reported $-1.131B in 2025. Projections indicate $-609M in 2027, and $-187M in 2028.